3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
NSCLC
1
Mesothelioma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Small Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
44
Carboplatin
17
Pemetrexed
14
Paclitaxel
13
Cisplatin
13
lenvatinib
5
Etoposide
5
Docetaxel
5
epacadostat
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
durvalumab
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
olaparib
2
Saline Solution
2
Immune Checkpoint Inhibitors
2
Dexamethasone
2
Acetaminophen
2
sacituzumab govitecan
1
ribociclib
1
patritumab deruxtecan
1
osimertinib
1
etoposide phosphate
1
efineptakin alfa
1
cemiplimab
1
camrelizumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Diphenhydramine
×
Thoracic
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts